XML 162 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
REVENUES:        
Total revenues $ 501,693 $ 429,485 $ 987,723 $ 931,554
OPERATING EXPENSES:        
Cost of sales 127,062 97,967 247,228 209,341
Research and development 161,107 182,139 309,832 324,396
Selling, general and administrative 184,161 175,412 358,479 362,707
Intangible asset amortization and contingent consideration 17,691 14,912 35,426 30,589
Gain on sale of nonfinancial assets 0 0 0 (59,495)
Total operating expenses 490,021 470,430 950,965 867,538
INCOME (LOSS) FROM OPERATIONS 11,672 (40,945) 36,758 64,016
Equity in the loss of BioMarin/Genzyme LLC (175) (79) (1,526) (156)
Interest income 4,471 4,291 6,910 9,535
Interest expense (3,817) (8,048) (7,621) (14,963)
Other income, net 2,005 2,508 2,863 647
INCOME (LOSS) BEFORE INCOME TAXES 14,156 (42,273) 37,384 59,079
Provision for (benefit from) income taxes 1,215 (13,090) 7,072 6,881
NET INCOME (LOSS) $ 12,941 $ (29,183) $ 30,312 $ 52,198
NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share) $ 0.07 $ (0.16) $ 0.17 $ 0.29
NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share) $ 0.07 $ (0.16) $ 0.16 $ 0.28
Weighted average common shares outstanding, basic (in shares) 182,844 180,729 182,311 180,314
Weighted average common shares outstanding, diluted (in shares) 185,427 180,729 185,089 184,344
COMPREHENSIVE INCOME (LOSS) $ 6,998 $ (33,260) $ 45,512 $ 62,084
Net product revenues        
REVENUES:        
Total revenues 486,670 419,032 954,439 908,075
Royalty and other revenues        
REVENUES:        
Total revenues $ 15,023 $ 10,453 $ 33,284 $ 23,479